|Videos|July 27, 2015
Mechanisms of Action for New Weight-Loss Agents
Advertisement
Episodes in this series
Jennifer L. Costello, PharmD, BCPS, BC-ADM, ambulatory care clinical pharmacist at Saint Barnabas Medical Center, reviews the pharmacologic mechanisms in the new weight-loss drugs.
Liraglutide, a glucagon-like peptide-1 receptor agonist, helps improve insulin secretion and reduce glucagon release. The drug dramatically affects patient satiation, so they eat less, Dr. Costello notes. It also causes some gastrointestinal upset, which can make some patients eat less.
Meanwhile, the naltrexone/bupropion combination affects central nervous system synapses by augmenting or modulating the craving zone—causing patients to have fewer food cravings.
Advertisement
Related to this article
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Category 1 placement for belantamab mafodotin plus bortezomib and dexamethasone puts guideline support ahead of the FDA label.
No new vouchers have been awarded since former FDA Commissioner Marty Makary left the agency in May, though HHS maintains the pilot is ongoing.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Nicole Albanese, PharmD, explains how a structured testing schedule and simple notes help patients bring useful glucose data to their care team.
Garlic has a long history in traditional medicine, but evidence for its benefits varies by preparation, and patients taking medications that increase bleeding risk should use it with caution.
About 89% of Americans live within 5 miles of a pharmacy, but proximity says little about whether they can afford their medications or get real counseling.
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
2
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
3
FDA Reportedly Shelves Commissioner's National Priority Voucher Program
4
Inside the OCEANIC-STROKE Trial and What Asundexian Means for the Future of Stroke Prevention
5